Consider a woman moving through various stages in her life. She begins tracking her menstrual cycle as a teenager, weighs fertility decisions in her thirties, manages perimenopause in her forties and confronts cardiovascular and bone health in the decades that follow. Her health is one continuous journey. Yet the way our industry has marketed to her tells a different story.
Women are faced with a series of disconnected and disjointed campaigns that only address a single condition or an isolated event. This creates a world that presumes she has arrived without a past and will leave without a clear path forward. We initiate, engage and move on and later we will reintroduce ourselves to the same woman that we have effectively already met.
The brands that will be leaders in women's health will stop marketing isolated episodes and instead start building a partnership that spans a lifetime.
There is also an economic argument for the necessary shift in mindset and approach. The World Economic Forum and the McKinsey Health Institute report that women spend 25% more of their lives in poor health than men and that closing the women's health gap could add at least $1 trillion to global GDP annually by 2040. The foundation of the neglect behind that figure is represented by the paltry 1% of health care research and innovation funding directed to female-specific conditions–beyond oncology–according to McKinsey. It is a story of a market that has underserved its most influential decision-maker, the woman who, per the U.S. Department of Labor, makes roughly 80% of the health care decisions for her family.
The market is ready. PwC describes women's health shifting from margin to mainstream. Marketers need to acknowledge this as a longitudinal opportunity. Silicon Valley Bank recorded $2.6 billion in dedicated women's health venture funding in 2024, a 55% increase that outpaced the broader health care market. The capital is arriving. Marketers need to be proactive. The question for pharmaceutical leaders is no longer whether to invest, but rather how to engage in a way the previous model could not achieve.
This is where AI could transform engagement, not just peripherally but at the core. The historical constraint was structural, where a brand would speak to a woman about fertility or menopause, but it could not connect those conversations across time, because the data too often lived in separate systems. AI could dissolve that constraint by integrating hormonal, metabolic and behavioral signals with real-world evidence. It would allow a brand to understand where a woman is in her health journey and anticipate multiple paths forward. The result is not bolder messaging, but more relevant engagement. AI could not only support the dialogue with HCPs, patient communication leaders and patients but also influence the industry itself. AI could help shift the paradigm from treating a condition to providing preventive care to a woman.
Adoption is already here. NVIDIA's 2026 survey found that 70% of health care and life sciences organizations are now actively using AI, which is an increase from 63% in 2025 and has shown that 85% have reported that it has increased revenue. The tools exist. The capability exists. The differentiation for marketers will now come from how AI is appropriately and responsibly utilized to support behavior change.
We are at the precipice where discipline matters most. Women's health audiences have long memories and finely tuned instincts for what is performative. For example, The Gender Pain Gap Index Report found that 56% of women feel their pain is ignored or dismissed. A brand that deploys AI to extract critical insights can earn trust over time. AI can quickly conduct analysis and marketers can create engagement that guards against bias while ensuring a more personalized approach. AI can help transform a patient case number into an understanding of who that individual is.
The choice in front of our industry is the familiar one between reactive and proactive. A brand can continue to fund single-condition campaigns and rediscover the same woman every few years or it can build the data foundation and the governance to walk beside her across all of her life stages. One approach treats women's health as a series of transactions. The other approach treats it as a relationship. The brands that choose the relationship will not only close the gap. They will define what comes next.
Please click here for a complete list of references.
Jennifer M. Barrett, MSc is SVP of client services at Woven Health Collective, an agency partner that delivers trusted AI solutions with in-house expertise.
